The lack of monotherapeutic efficacy, refractory disease, acquired resistance, and relapse following FLT3 TKI treatment underscores the need to exploit novel drugs for effective combinatory therapy for AML patients [11, 15, 16]. Here, FLT3 is linked to acute myeloid leukemia.